Dec 07, 2015 7:00am EST Can-Fite Subsidiary, OphthaliX, Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101
Nov 23, 2015 7:00am EST Can-Fite Announces Compelling Pre-Clinical Data on CF102 in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Oct 26, 2015 7:00am EDT Can-Fite to Participate in BIO-Europe Partnering Conference on November 2-5, 2015 in Munich, Germany
Oct 22, 2015 7:00am EDT New Study Demonstrates CF602 Mechanism of Action to Improve Sexual Dysfunction
Oct 12, 2015 7:00am EDT European Medicines Agency Grants Orphan Designation to Can-Fite's CF102 in the Treatment of Liver Cancer
Oct 07, 2015 7:00am EDT Can-Fite to Deliver 2 Presentations on its Cancer Drug CF102 at the 20th World Congress on Advances in Oncology and 18th International Symposium on Molecular Medicine on October 8-10, 2015 in Athens
Sep 29, 2015 10:11am EDT Can-Fite to Present CF101 Psoriasis Data at Late Breaking Session of the EADV Congress in Copenhagen on October 10, 2015
